Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • Myelodysplastic Syndromes (MDS)
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Myeloproliferative Neoplasms
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
    • Browse Research
      • Mismatched donor sources may fill an unmet need for patients without fully matched family or unrelated donors
      • Hematopoietic cell donor type may not impact quality of life post-transplant
      • Novel three-drug combination improves GVHD-free and relapse-free survival and relapse after allogeneic transplant
      • Long-term risks of hematological malignancy, autoimmune or thrombotic events do not differ in bone marrow and filgrastim-mobilized PBSC donors
      • Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT
      • Linkage across research databases may provide a more complete understanding of HCT patient outcomes
      • Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes
      • Factors associated with young adults opting out of donation for HCT may provide insights into donor availability
      • Alternative donor HCT may yield comparable outcomes and expand access for myelofibrosis patients
      • Younger matched unrelated donors may reduce relapse risk after allogeneic HCT compared to using older matched sibling donors
      • Allogeneic HCT may be a better option for older patients with AML than conventional consolidation therapy
    • Education Catalog
      • State of the Science in Ensuring a Donor for All
      • Predicting and Addressing Relapse After HCT
      • After the Results Quality of Life Pre- and Post-Transplant
      • Overcoming Challenges in Cell and Gene Therapy Trials Part 2
      • Overcoming Challenges in Cell and Gene Therapy Trials Part 1
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
    • Local Provider Partnership Program
  • Early Complications
  • Vaccinations
  • Long-Term Care Guidelines
  • Chronic GVHD
  • Post-Transplant Guidelines

Chronic GVHD

  • Skin
  • Nails
  • Scalp and Body Hair
  • Eyes
  • Mouth
  • Lungs
  • Muscles, Fascia, Joints
  • Hematopoietic & Immune
  • GI Tract
  • Liver
  • Genitalia
  • Other
Research Spotlight
  • A safe and effective shared care approach after allogeneic HCT could be a new standard of care

    December 2022

  • Lack of collaborative relationships between physician teams associated with HCT care decisions

    April 2022

  • Haploidentical HCT is viable alternative to matched sibling HCT in patients with AML in CR1

    July 2019

  • Post-Transplant Care
  • Chronic GVHD
  • Email
  • Print This Page

Related Resources

  • HCT Guidelines App
  • Post-HCT Care Education
  • Long-Term Care Guidelines

Patient Resources

  • Post-Bone Marrow Transplant Guidelines
  • Allogeneic Transplant Process Booklet
  • Chronic GVHD Video

Chronic GVHD

Chronic graft-versus-host disease (GVHD), an immune response of the donor-derived T cells against recipient tissues, occurs in approximately 30-70% of patients receiving an allogeneic transplant. This is a serious, potentially life-threatening post-transplant complication. Early detection of chronic GVHD can help prevent irreversible organ damage and increase the quality-of-life of transplant recipients.

With early detection and advances in understanding the underlying mechanisms of the disease, it may be possible to reduce the morbidity and mortality of this major complication of allogeneic transplantation.

Optimal treatment of chronic GVHD requires a multidisciplinary team approach in making the diagnosis, prompt implementation of systemic and topical treatment, periodic monitoring of the response during the course of disease, calibration of treatment intensity and the use of supportive care to prevent complications and disability. [1]

Screening for Chronic GVHD

Identify clinical manifestations that are potential early indicators of chronic GVHD. If GVHD is suspected, timely collaboration with the patient's transplant center is recommended to confirm the diagnosis and develop and evaluate a treatment plan.

Access Guidelines by Organ/Site:

  • Skin*
  • Nails*
  • Scalp/body hair*
  • Eyes*
  • Mouth*
  • Lungs
  • Muscles, fascia, joints*
  • GI tract
  • Liver
  • Genitalia
  • Hematopoietic/Immune
  • Other manifestations

(Pages marked with asterisks have photos of clinical manifestations of chronic GVHD.)

These guidelines are based on published diagnostic criteria from the National Institutes of Health (NIH) Consensus Development Project on chronic GVHD [2,3,4] and are included in our HCT Guidelines.

  • View Long-Term Care Guidelines (PDF)
  • Order print version or access the HCT Guidelines mobile app

References

  1. Flowers MED, Martin P. How we treat chronic graft-versus-host disease. Blood. 2015; 125(4): 606-615. Access
  2. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Response Criteria Working Group Report. Biol Blood Marrow Transplant. 2015; 21(3): 389-401. Access
  3. Lee SJ, Wolff D, Kitko C, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report. Biol Blood Marrow Transplant. 2015; 21(6): 984-999. Access
  4. These guidelines have been developed by the National Marrow Donor Program® (NMDP)/Be The Match® in consultation with Sandra A. Mitchell, CRNP, MScN, AOCN; National Institutes of Health Clinical Center; and Steven Z. Pavletic, M.D.; National Cancer Institute, National Institutes of Health, Bethesda, Md. The information in this document does not represent the official position of the NIH or the U.S. Government.
  • Email
  • Print This Page

Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

Transplant Indications and Outcomes

  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources

  • Patient Resources
  • Financial Resources
  • Obstetrician Resources
  • Technique Videos
  • Umbilical Cord Blood Collection Training for Public Donation
  • Local Provider Partnership Program

Contact Us

National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright